• Urogynaecology
  • Oral cavity
  • Instrument class
  • Surgical retractor series
  • Confort Ostomy Products
  • Enzyme Detergent
  • Suture applier
  • Synthetic bone substitute
  • High frequency electrode
  • I  MODENA  retractor
  • II  NATHANSON  retractor
  • III MAXOP  retractor
  • IV  low rectal cancer retractor
  • Kasios TCH
  • Kasios TCP
  • Injectable synthetic bone substitute
  • Bone fuse apparatus
  • [中文版] [English]
  • Company news
  • Industry news
  •  
    AOTI Enters Into Multi-Million USD Strategic Relationship for Chinese Market
    Add Time:2019-01-17    Editor:admin    Read:247
    AOTI Enters Into Multi-Million USD Strategic Relationship for Chinese Market

    AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen (TWO2) therapy wound healing products into the People’s Republic of China.The multi-year agreement includes minimum sales performance expectations totaling close to $18 million.


     


    Both companies are initially working closely together to achieve National Medical Products Administration (NMPA) registration and approval for the TWO2therapy product line in China, while in parallel generating market awareness and clinical acceptance of this unique therapy across the country. Following this initial phase and after gaining marketing approval, Nanning will aggressively market the product line nationwide through both its direct sales force and network of regional distribution partners.





    “We are delighted to enter into this unique collaboration with such a respected partner that will allow our revolutionary TWO2 therapy to be quickly made available to the millions of Chinese patients suffering with non-healing wounds” stated Dr. Mike Griffiths, President and Chief Executive Officerof AOTI Inc.



     

     

    With a growing prevalence, it is estimated that there are at least 109.6 million adults with diabetes in China already, resulting inover 16 million patients that are likely suffering from Diabetic Foot Ulcers (DFU) alone.Resultantly, China's healthcare market is growing at an unprecedented CAGR of about 12%. With healthcare spending expected to reach $1 trillion by 2020.

     

     

     


    Our company has been searching for products that can make real impact in healing chronic wounds, such as Diabetic Foot Ulcers, which afflict such a large number of people across China” stated Peter Pan, President and Chief Executive Officer of Nanning Xinzizhu Trading Co.,Ltd. He further commented that “with our experience in the surgical and wound care sector, combined with our expertise in launching new product across China, we believe we can grow this business opportunity exponentially in the coming years.”


    Nanning XINZIZHU Trading CO.,Ltd   Tel:0771-5349099 2815868   Fax:0771-2815868
    Address: Room 304,Xingdao International,Singapore Industrial Park,No.10,Zhujin Road ,Qingxiu District, Nanning,Guangxi,China